Transchem Corporation Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 106.00 Cr
About Transchem Corporation Pharma
Transchem Corporation Pharma Private Limited (TCPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 March 2022 (Two years and ten months 19 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹106.00 Cr.
Zubin Zaveri and Shivang Zaveri serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909MH2022PTC378924
-
Company No.
378924
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Mar 2022
-
Date of AGM
29 Aug 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Transchem Corporation Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zubin Zaveri
|
Director | 23-Mar-2022 | Current |
|
Shivang Zaveri
|
Director | 23-Mar-2022 | Current |
Financial Performance of Transchem Corporation Pharma.
Transchem Corporation Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Transchem Corporation Pharma?
In 2023, Transchem Corporation Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹106.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 77.00 Cr
- Citi Bank N.A. : 15.00 Cr
- Yes Bank Limited : 14.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Apr 2024 | Hdfc Bank Limited | ₹43.00 Cr | Open |
| 12 Dec 2023 | Hdfc Bank Limited | ₹34.00 Cr | Open |
| 29 Mar 2023 | Citi Bank N.A. | ₹15.00 Cr | Open |
| 23 Dec 2022 | Yes Bank Limited | ₹14.00 Cr | Open |
How Many Employees Work at Transchem Corporation Pharma?
Transchem Corporation Pharma has a workforce of 43 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Transchem Corporation Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Transchem Corporation Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.